JAAD OnlineReply to: “COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated”
Cited by (0)
Authors Pahalyants and Murphy are cofirst authors.
Funding sources: None.
Key words: COVID-19 vaccination; immune-mediated inflammatory diseases; rituximab.
Reprints not available from the authors.
IRB approval status: This study received approval from the Massachusetts General Hospital Institutional Review Board.
© 2022 by the American Academy of Dermatology, Inc.